title: Antimalarials during pregnancy: a cost-effectiveness analysis.
abstract: Antenatal clinics (ANC) provide an avenue for interventions that promote maternal and infant health. In areas hyperendemic for Plasmodium falciparum, malaria infection during pregnancy contributes to low birth weight (LBW), which is the greatest risk factor for neonatal mortality. Using current data and costs from studies in Malawi, a decision-analysis model was constructed to predict the number of LBW cases prevented by three antimalarial regimens, in an area with a high prevalence of chloroquine (CQ)-resistant malaria. Factors considered included local costs of antimalarials, number of ANC visits, compliance with dispensed antimalarials, prevalence of placental malaria, and LBW incidence. For a hypothetical cohort of 10,000 women in their first or second pregnancy, a regimen consisting of one dose of sulfadoxine-pyrimethamine (SP) in the second trimester followed by a second dose at the beginning of the third trimester would prevent 205 cases of LBW at a cost of US$ 9.66 per case of LBW prevented. A regimen using a treatment dose of SP followed by CQ 300 mg (base) weekly would prevent 59 cases of LBW at a cost of $62 per case prevented, compared with only 30 cases of LBW prevented at a cost of $113 per case when the regimen involves initial treatment with CQ (25 mg/kg) followed by CQ 300 mg (base) weekly. In areas hyperendemic for CQ-resistant P. falciparum, a two-dose SP regimen is a cost-effective intervention to reduce LBW incidence and it should be included as part of the antenatal care package.
authors.affiliation: Division of Parasitic Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, GA 30333, USA.
authors.forename: L J
authors.initials: LJ
authors.lastname: Schultz
authors.forename: R W
authors.initials: RW
authors.lastname: Steketee
authors.forename: L
authors.initials: L
authors.lastname: Chitsulo
authors.forename: J J
authors.initials: JJ
authors.lastname: Wirima
mesh_terms: D000962:Antimalarials / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D002738:Chloroquine / Q000008:administration & dosage; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D016778:Malaria, Falciparum / Q000188:drug therapy*; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000188:drug therapy*; D011739:Pyrimethamine / Q000008:administration & dosage; D013413:Sulfadoxine / Q000008:administration & dosage
chemical_list: D000962:Antimalarials; D004338:Drug Combinations; D013413:Sulfadoxine; D002738:Chloroquine; D011739:Pyrimethamine